Actuate Therapeutics’ (ACTU) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report published on Friday,Weiss Ratings reports.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. B. Riley assumed coverage on shares of Actuate Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Actuate Therapeutics in a research report on Tuesday, September 23rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.33.

Actuate Therapeutics Price Performance

Actuate Therapeutics stock opened at $7.20 on Friday. The stock’s 50-day moving average is $7.52 and its 200-day moving average is $7.95. The company has a market cap of $167.33 million, a price-to-earnings ratio of -6.15 and a beta of -0.23. Actuate Therapeutics has a 12 month low of $5.47 and a 12 month high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.11).

Hedge Funds Weigh In On Actuate Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACTU. Bank of America Corp DE boosted its position in Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after buying an additional 15,267 shares during the last quarter. Voss Capital LP lifted its stake in shares of Actuate Therapeutics by 101.0% in the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock worth $1,748,000 after acquiring an additional 143,759 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Actuate Therapeutics in the second quarter valued at about $105,000. Northwestern Mutual Wealth Management Co. grew its stake in Actuate Therapeutics by 492.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after purchasing an additional 15,393 shares in the last quarter. Finally, BIOS Capital Management LP grew its stake in Actuate Therapeutics by 0.7% during the 2nd quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock valued at $60,887,000 after purchasing an additional 71,428 shares in the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.